Navigation Links
Revised: Challenging the Norm May Lead to New Therapy for Type 2 Diabetes
Date:3/24/2008

GRAND RAPIDS, Mich., March 24 /PRNewswire/ -- What happens when leading biochemists get together to challenge conventional pharmaceutical theories? Often, incredible new drug therapies are born. Recently, this same scenario began when two former major pharma scientists challenged the concept behind the leading treatments for type 2 diabetes, a disease that impacts millions of Americans. They saw the side effects caused by the current therapy like edema and weight gain, and went to work on a hypothesis that the current receptor was leading to these side effects associated with PPAR-based therapies.

As non-conventional as the theory was, it's working. Drs. Jerry Colca and Rolf Kletzien, co-founders of Kalamazoo, Michigan-based Metabolic Solutions Development Company (MSDC), have completed Phase I clinical studies and just received second phase funding from a Michigan-based science fund. They have applied for an FDA fast-track review of their work.

"We are pleased that our lead compound performed so well in Phase I studies," said Colca, MSDC's chief scientific officer. "Pre-clinical studies suggest that this compound can deliver significant pharmacological benefit without the complications inherent in current PPAR-based therapies."


'/>"/>
SOURCE Metabolic Solutions Development Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Challenging the Norm May Lead to New Therapy for Type 2 Diabetes
2. New Study Reports That Physical Therapy Treatment Resolves Symptoms of Urinary Incontinence in Women
3. Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study
4. Totality of Available Data Reaffirms PROCRIT(R) (Epoetin alfa) Is Safe and Effective When Used Appropriately as Labeled to Treat Chemotherapy-Induced Anemia
5. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
6. Leukemia Therapy With Imatinib During Pregnancy May Cause Infant Abnormalities
7. Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema
8. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
9. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
10. ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
11. Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Consumers have taken ... regulators/payers have placed more emphasis on patient outcomes. ... support programs in the pharmaceutical industry have evolved ... Consequently, pharmaceutical companies are focusing on becoming more ... providing products and services that improve health. ...
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... Dublin ... of the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global ... including its applications in various applications. The report deals ... three main industries: pharmaceutical and biotechnology, food and beverage, ...
Breaking Medicine Technology:
(Date:6/26/2016)... North Carolina (PRWEB) , ... June 26, 2016 , ... ... release of a new product that was developed to enhance the health of felines. ... for centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
Breaking Medicine News(10 mins):